Tolerability and activity of weekly paclitaxel and carboplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Fabi, A
De Marco, S
Barduagni, M
Gamucci, T
Cortesi, E
De Marinis, F
Ferraresi, V
Saltarelli, R
Gabriele, A
Accettura, C
Cognetti, F
机构：
[1] Regina Elena Canc Inst, Rome, Italy
[2] ASL RMH, Rome, Italy
[3] Umberto I Hosp, Frosinone, Italy
[4] Umberto I Univ La Sapienza, Rome, Italy
[5] Forlanini Hosp, Rome, Italy
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A16
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [21] Weekly Paclitaxel with 4 Weekly Carboplatin as Salvage Treatment in Advanced Non-Small Cell Lung Cancer-HCG Center Experience
    Thungappa, Satheesh
    Patil, Shekar
    Shashidhara, H.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S897 - S897
  • [22] Weekly nab -paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Socinski, Mark A.
    Langer, Corey J.
    Okamoto, Isamu
    Hon, Jeremy K.
    Hirsh, Vera
    Dakhil, Shaker R.
    Page, Ray D.
    Orsini, James M.
    Zhang, Hui
    Renschler, Markus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [23] Weekly paclitaxel (P), carboplatin (C) and irinotecan (I), PCI, in patients with chemo-naive advanced non-small cell lung cancer (NSCLC)
    Chang, A
    LUNG CANCER, 2005, 49 : S240 - S240
  • [24] Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients
    Salim, Derya Kivrak
    Telli, Tugba Akin
    Tatli, Ali Murat
    Kilickap, Sadettin
    Yumuk, Perran Fulden
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (06) : 1137 - 1145
  • [25] A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer
    Inoue, A
    Usui, K
    Ishimoto, O
    Matsubara, N
    Tanaka, M
    Kanbe, M
    Gomi, K
    Koinumaru, S
    Saijo, Y
    Nukiwa, T
    LUNG CANCER, 2006, 52 (01) : 83 - 87
  • [26] The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias
    Minegishi, Yuji
    Sudoh, Junko
    Kuribayasi, Hideaki
    Mizutani, Hideki
    Seike, Masahiro
    Azuma, Arata
    Yoshimura, Akinobu
    Kudoh, Shoji
    Gemma, Akihiko
    LUNG CANCER, 2011, 71 (01) : 70 - 74
  • [27] Comparison of two different carboplatin and weekly paclitaxel schedule in elderly advanced non-small cell lung cancer patients
    Derya Kıvrak Salim
    Tuğba Akın Telli
    Ali Murat Tatlı
    Sadettin Kılıçkap
    Perran Fulden Yumuk
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 1137 - 1145
  • [28] Imprime PGG improves the efficacy of carboplatin, paclitaxel, and cetuximab chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC).
    Thomas, Michael
    Sadjadian, Parvis
    Kollmeier, Jens
    Hao, Zhonglin
    Patchen, Myra
    Lowe, Jamie
    Mattson, Paulette
    Huhn, Richard D.
    Bose, Nandita
    Antonysamy, Mary
    Gargano, Michele
    Gordon, Keith
    Schneller, Folker
    CLINICAL CANCER RESEARCH, 2014, 20
  • [29] Meloxicam (M) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced non-small cell lung cancer (NSCLC).
    Takahashi, T
    Kogure, Y
    Ueda, S
    Ebisawa, M
    Asai, G
    Yamamoto, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 649S - 649S
  • [30] A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
    Jordi Rodon
    Charlotte D. Jacobs
    Quincy Chu
    Eric K. Rowinsky
    Arturo Lopez-Anaya
    Chris H. Takimoto
    Heather A. Wakelee
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 825 - 834
12345